title: Multifunctional CD40L: pro- and anti-neoplastic activity.
abstract: The CD40 ligand is a type I transmembrane protein that belongs to a tumor necrosis factor (TNF) superfamily. It is present not only on the surface of activated CD4+ T cells, B cells, blood platelets, monocytes, and natural killer (NK) cells but also on cancer cells. The receptor for ligand is constitutively expressed on cells, TNF family protein: CD40. The role of the CD40/CD40L pathway in the induction of body immunity, in inflammation, or in hemostasis has been well documented, whereas its involvement in neoplastic disease is still under investigation. CD40L ligand may potentiate apoptosis of tumor cells by activation of nuclear factor-κB (NF-κB), AP-1, CD95, or caspase-depended pathways and stimulate host immunity to defend against cancer. Although CD40L has a major contribution to anti-cancer activity, many reports point at its ambivalent nature. CD40L enhance release of strongly pro-angiogenic factor, vascular endothelial growth factor (VEGF), and activator of coagulation, TF, the level of which is correlated with tumor metastasis. CD40L involvement in the inhibition of tumor progression has led to the emergence of not only therapy using recombinant forms of the ligand and vaccines in the treatment of cancer but also therapy consisting of inhibiting platelets-main source of CD40L. This article is a review of studies on the ambivalent role of CD40L in neoplastic diseases.
authors.affiliation: Department of Clinical Laboratory Diagnostics, Medical University of Bialystok, Bialystok, Poland, alex.korniluk@wp.pl.
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Korniluk
authors.forename: Halina
authors.initials: H
authors.lastname: Kemona
authors.forename: Violetta
authors.initials: V
authors.lastname: Dymicka-Piekarska
mesh_terms: D000818:Animals; D023201:CD40 Ligand / Q000378:metabolism*; D006801:Humans; D009369:Neoplasms / Q000378:metabolism*
chemical_list: D023201:CD40 Ligand